 There are 3 phases in this study. Phase 1 is screening phase. Each subject will be evaluated to determine if heshe is eligible for the study. Phase 2 is the intervention phage. Patients are divided arbitrarily into two groups according to baseline RRF residual glomerular filtration rate rGFR 5or 5 mlmin, then randomly received 12 months treatment with the study drugs furosemide 120mg daily, 60mg daily, or no diuretic. Phase 3 is following-up phase, which lasts 1 year. Dialytic prescription is adjusted independent of the study and is guided by clinical parameters and calculated clearances target creatinine clearance 65Lweek, urea clearance KtV 1.7 per week. Blood pressure is measured using an automated blood pressure device, and the target level is 13585mmHg. The antihypertensive medication is introduced after the body weigh reduced into target level, and the ACEI and or ARB selection is needed to the cross-sectional design. The hydration state is measured by bioelectrical impedance analysis BIA. 